10-year

10-Year Anniversary Promotion (20% off)

Join GuruFocus Premium Membership Now for Only $279/Year

Once a decade discount

Save up to $500 on Global Membership.

Don't Miss It !

Free 7-day Trial
All Articles and Columns »

Vanguard Health Care Fund Buys Ironwood Pharmaceuticals Inc., Johnson & Johnson, Boston Scientific Corp., Sells Amylin Pharmaceuticals Inc., Mead Johnson Nutrition, Novartis Ag

Edward Owens manages Vanguard Health Care Fund. Since inception in 1984, his fund has gained 16.8% a year. The fund lost more than 3% this year. These are the first quarter portfolio update of his fund.

Edward Owens buys Ironwood Pharmaceuticals Inc., sells Ims Health Inc. during the 3-months ended 03/31/2010, according to the most recent filings of his investment company, Vanguard Health Care Fund. Edward Owens owns 79 stocks with a total value of $18.5 billion. These are the details of the buys and sells.

For the details of Edward Owens's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Edward+Owens

This is the sector weightings of his portfolio:

Health Care 61.4%
Consumer Services 8%
Technology 1.5%
Industrials 0.8%
Financials 0.6%
Consumer Goods 0.1%


These are the top 5 holdings of Edward Owens

  1. Merck & Co. Inc. (MRK) - 33,630,248 shares, 6.78% of the total portfolio. Shares reduced by 0.88%
  2. Forest Laboratories Inc. (FRX) - 29,933,000 shares, 5.07% of the total portfolio. Shares reduced by 0.66%
  3. Pfizer Inc (PFE) - 43,259,788 shares, 4.01% of the total portfolio.
  4. McKesson Corp. (MCK) - 11,189,900 shares, 3.97% of the total portfolio.
  5. Eli Lilly And Company (LLY) - 19,879,900 shares, 3.89% of the total portfolio.


Added: Johnson & Johnson (JNJ)

Edward Owens added to his holdings in Johnson & Johnson by 47.06%. His purchase prices were between $62.37 and $65.36, with an estimated average price of $63.98. The impact to his portfolio due to this purchase was 0.56%. His holdings were 5,000,000 shares as of 03/31/2010.

Johnson & Johnson is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world. Johnson & Johnson has a market cap of $174.75 billion; its shares were traded at around $63.4 with a P/E ratio of 13.6 and P/S ratio of 2.8. The dividend yield of Johnson & Johnson stocks is 3.1%. Johnson & Johnson had an annual average earning growth of 11.1% over the past 10 years. GuruFocus rated Johnson & Johnson the business predictability rank of 4.5-star.

Added: Boston Scientific Corp. (BSX)

Edward Owens added to his holdings in Boston Scientific Corp. by 119.57%. His purchase prices were between $6.8 and $9.62, with an estimated average price of $8.14. The impact to his portfolio due to this purchase was 0.43%. His holdings were 20,200,000 shares as of 03/31/2010.

Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of minimally invasive medical devices. Boston Scientific Corp. has a market cap of $9.99 billion; its shares were traded at around $6.59 with a P/E ratio of 10.7 and P/S ratio of 1.3. Boston Scientific Corp. had an annual average earning growth of 5.4% over the past 10 years.

New Purchase: Ironwood Pharmaceuticals Inc. (IRWD)

Edward Owens initiated holdings in Ironwood Pharmaceuticals Inc.. His purchase prices were between $11.5 and $14.63, with an estimated average price of $13.03. The impact to his portfolio due to this purchase was 0.15%. His holdings were 2,000,000 shares as of 03/31/2010.

Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company that discovers, develops, and intends to commercialize innovative human medicines. Ironwood Pharmaceuticals Inc. has a market cap of $231.5 million; its shares were traded at around $12.08 .

Reduced: Amylin Pharmaceuticals Inc. (AMLN)

Edward Owens reduced to his holdings in Amylin Pharmaceuticals Inc. by 11.38%. His sale prices were between $22.67 and $22.95, with an estimated average price of $22.81. The impact to his portfolio due to this sale was -0.02%. Edward Owens still held 1,557,200 shares as of 03/31/2010.

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin Pharmaceuticals Inc. has a market cap of $2.66 billion; its shares were traded at around $18.54 with and P/S ratio of 3.6.

Reduced: Novonordisk A/s (NVO)

Edward Owens reduced to his holdings in Novonordisk A/s by 12.5%. His sale prices were between $63.85 and $79.13, with an estimated average price of $71.13. The impact to his portfolio due to this sale was -0.04%. Edward Owens still held 700,000 shares as of 03/31/2010.

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Novonordisk A/s has a market cap of $49.39 billion; its shares were traded at around $79.66 with and P/S ratio of 5.1. The dividend yield of Novonordisk A/s stocks is 1.2%.

Reduced: Mead Johnson Nutriti (MJN)

Edward Owens reduced to his holdings in Mead Johnson Nutriti by 21.12%. His sale prices were between $43.62 and $52.35, with an estimated average price of $47.55. The impact to his portfolio due to this sale was -0.12%. Edward Owens still held 2,068,137 shares as of 03/31/2010.

Mead Johnson Nutrition Company is a pediatric nutrition company. Mead Johnson Nutriti has a market cap of $9.86 billion; its shares were traded at around $48.2 with a P/E ratio of 20.9 and P/S ratio of 3.5. The dividend yield of Mead Johnson Nutriti stocks is 1.9%.

Reduced: Osi Pharmaceuticals Inc. (OSIP)

Edward Owens reduced to his holdings in Osi Pharmaceuticals Inc. by 13.02%. His sale prices were between $30.92 and $60.06, with an estimated average price of $42.79. The impact to his portfolio due to this sale was -0.14%. Edward Owens still held 3,340,873 shares as of 03/31/2010.

Osi Pharmaceuticals is one of the pharmaceutical research and development organizations, commercializing its skills in drug discovery, preclinical research, and drug development. Osi Pharmaceuticals Inc. has a market cap of $3.34 billion; its shares were traded at around $57.33 with a P/E ratio of 27.2 and P/S ratio of 7.7.

Reduced: Novartis Ag (NVS)

Edward Owens reduced to his holdings in Novartis Ag by 27.16%. His sale prices were between $51.91 and $55.52, with an estimated average price of $54.06. The impact to his portfolio due to this sale was -0.49%. Edward Owens still held 6,169,880 shares as of 03/31/2010.

Novartis AG is committed to improving health and well-being through innovative products and services. Novartis Ag has a market cap of $109.72 billion; its shares were traded at around $48.31 with a P/E ratio of 13.1 and P/S ratio of 2.6. The dividend yield of Novartis Ag stocks is 3.4%. Novartis Ag had an annual average earning growth of 14.2% over the past 10 years. GuruFocus rated Novartis Ag the business predictability rank of 5-star.


Rating: 2.0/5 (11 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK